Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "FGF19" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fibroblast growth factor 19 is a protein that in humans is encoded by the FGF19 gene. It functions as a hormone, regulating bile acid synthesis, with effects on glucose and lipid metabolism. Reduced synthesis, and blood levels, may be a factor in chronic bile acid diarrhea and in certain metabolic disorders.
Compositions, uses and methods for treatment of metabolic disorders and diseases
ActiveUS20130023474A1Lower Level RequirementsIncrease insulin sensitivityOrganic active ingredientsFungiDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
Owner:NEW YORK UNIV
Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
ActiveUS8951966B2Lower Level RequirementsIncrease insulin sensitivityOrganic active ingredientsBacteriaDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Compositions and methods for treatment of metabolic disorders and diseases
InactiveUS20150291677A1Effective treatmentPromote sugar metabolismBacteriaPeptide/protein ingredientsDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
ActiveUS9089525B1Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsMetabolism disorderDiseaseAcute hyperglycaemia
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Compositions comprising variants and fusions of FGF19 polypeptides
ActiveUS9290557B2Reduced glucose levelIncrease insulin sensitivityBacteriaPeptide/protein ingredientsAcute hyperglycaemiaFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ActiveUS20170182123A1Improves bile acid homeostasisReduce doseAntibody mimetics/scaffoldsSulfonylurea active ingredientsDiseaseFGF19
Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
Owner:NGM BIOPHARMLS
Compositions, uses and methods for treatment of metabolic disorders and diseases
InactiveUS20160200788A1Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsMetabolism disorderDiseaseFGF19
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Methods and compositions for the treatment of metabolic disorders and diseases
ActiveUS20170182122A1Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsBiological material analysisDiseaseFGF19
Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
InactiveUS9963494B2Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAcute hyperglycaemia
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
ActiveUS20180177846A1Improves bile acid homeostasisCompound screeningApoptosis detectionFGF19Peptide sequence
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ActiveUS10456449B2Reduce doseReduce frequencyAntibody mimetics/scaffoldsSulfonylurea active ingredientsDiseaseFGF19
Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
Owner:NGM BIOPHARMLS
Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Nonalcoholic Fatty Liver Disease
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Novel therapeutic use of fgf19
ActiveUS20180369331A1Increasing muscle fiber sizeIncrease in sizePeptide/protein ingredientsMuscular disorderPhysiologyFGF19
Owner:UNIV CLAUDE BERNARD LYON 1 +3
Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Cirrhosis
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Liver Fibrosis
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
InactiveUS10398758B2Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsBiological material analysisDiseaseAcute hyperglycaemia
Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
ActiveUS20170096462A1Improve stabilityHigh affinityCompound screeningApoptosis detectionFGF19C-terminus
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
Owner:NEW YORK UNIV
Methods of treating gastrointestinal motility-related disorders using variants and fusions of fgf19/fgf21 polypeptides
InactiveUS20200330555A1Treating or preventing the gastrointestinal motility-related disorderTreating and preventing constipationPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseFGF19
Provided herein are methods of treating or preventing gastrointestinal motility-related disorders, treating or preventing constipation or stimulating bowel function, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics).
Owner:NGM BIOPHARMLS
Methods and Compositions for the Treatment of Metabolic Disorders and Diseases
InactiveUS20200054714A1Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsBiological material analysisDiseaseFGF19
Owner:NGM BIOPHARMLS
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ActiveUS20200197489A1Reduce doseReduce frequencyAntibody mimetics/scaffoldsSulfonylurea active ingredientsDiseaseFGF19
Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
Owner:NGM BIOPHARMLS
FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
The present invention describes methods for diagnosing, treating and determining the prognosis of breast cancer HR+ patient, the methods including detecting the amplification of one or more biomarkers comprising a FGFR ligand such as FGF3, FGF4, FGF19, and / or a FGFR, such as for example FGFR1 in a subject; determining an FGFR1 inhibitor for treating the subject based on the amplification of the one or more biomarkers in the subject; administering to the subject in need thereof the FGFR1 inhibitor and using the one or more biomarkers to indicate prognosis of the subject treated with the FGFR1 inhibitor.
Owner:NOVARTIS AG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com